Contact Us

Yes. ITGAE rescue experiments require attention to αEβ7 heterodimer formation: • Construct design: use a codon-modified ITGAE sequence with a small intracellular C-terminal tag (FLAG, HA). ITGAE has the canonical α-integrin architecture with β-propeller and I domain — preserve all elements. • Surface localization validation: confirm αEβ7 heterodimer surface expression before functional assays. • E-cadherin-binding-deficient rescue: I domain MIDAS site mutations abolish E-cadherin binding and serve as the standard specificity control. • ITGB7 partnership: ITGAE requires ITGB7 for surface expression — rescue interpretation considers β7 levels. • Functional readout: rescue should restore αEβ7-dependent binding to E-cadherin-expressing epithelial cells. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying IGF1R's role in lung cancer biology or modeling EGFR-TKI resistance mechanisms involving IGF1R signaling. The Knockout line is the standard tool for asking whether IGF1R is required for lung cancer proliferation and survival in NSCLC context — IGF1R amplification, autocrine IGF-1/IGF-2 signaling, and IGF1R-mediated resistance to EGFR-targeted therapy have been characterized in lung cancer. Overexpression is useful for studying IGF1R amplification effects in lung cancer. For lung cancer research, the EDITGENE IGF1R Knockout in A-549 is highly relevant — A-549 is an NSCLC cell line, and IGF1R signaling has been implicated in NSCLC progression and treatment resistance. This product complements the parallel IGF1R Knockout in HEK293 (also available); A-549 is preferred for lung cancer-relevant studies, HEK293 for systematic biochemistry. Rescue with wild-type or kinase-dead IGF1R is the standard specificity control. The knockout is valuable for studying IGF1R-EGFR signaling crosstalk, EGFR-TKI resistance mechanisms, and IGF1R-targeted therapy in lung cancer.

Yes. IGF1R rescue experiments in A-549 are well-suited for lung cancer research: • Construct design: use a codon-modified IGF1R sequence with a small intracellular C-terminal tag (FLAG, HA). Preserve α2β2 tetramer architecture. • Surface localization validation: confirm plasma membrane localization before functional assays. • Kinase-dead rescue: K1003A mutation abolishes catalytic activity. • EGFR-TKI resistance studies: rescue with wild-type IGF1R in A-549 enables assessment of IGF1R contribution to EGFR-TKI resistance. • Functional readout: rescue should restore IGF-1-induced IGF1R signaling and lung cancer proliferation. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ITGB1 (integrin β1)'s role as the most broadly expressed integrin β-subunit or its functions in lung cancer adhesion, migration, and ECM signaling. The Knockout line is the standard tool for asking whether β1 is required for these processes — ITGB1 partners with 12 different α-subunits (ITGA1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, V) to form the largest integrin subfamily, binding to fibronectin, collagen, laminin, and other ECM ligands. Overexpression is useful for studying β1-integrin in heterologous expression contexts. For lung cancer research, the EDITGENE ITGB1 Knockout in A-549 is highly relevant — A-549 is an NSCLC model, and β1-integrin is implicated in lung cancer progression and therapy resistance. Rescue with wild-type or ligand-binding-deficient ITGB1 is the standard specificity control. The knockout is valuable for studying lung cancer-ECM interactions, β1-integrin-mediated drug resistance, and emerging β1-integrin-targeted cancer therapeutics.

Yes. ITGB1 rescue experiments require attention to heterodimer formation: • Construct design: use a codon-modified ITGB1 sequence with a small intracellular C-terminal tag (FLAG, HA). ITGB1 has the canonical β-integrin architecture — preserve all elements including the cytoplasmic NPxY motifs for adaptor protein binding. • Surface localization validation: confirm β1-heterodimer surface expression before functional assays. • Ligand-binding-deficient rescue: β-I domain MIDAS site mutations abolish ECM ligand binding. • α-subunit considerations: ITGB1 partners with 12 different α-subunits — rescue interpretation considers α-subunit expression patterns determining ECM ligand specificity. • Functional readout: rescue should restore ECM adhesion and integrin-mediated signaling. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ITGB8 (integrin β8)'s role as a TGF-β-activating integrin or its functions in vascular development and immune regulation. The Knockout line is the standard tool for asking whether ITGB8 is required for these processes — ITGB8 partners exclusively with ITGAV (αv) to form the αvβ8 integrin, which uniquely activates latent TGF-β through binding the RGD motif of the latent TGF-β complex without requiring intracellular force, distinct from other αv-integrins. Overexpression is useful for studying ITGB8 gain-of-function effects. For TGF-β and integrin research, the EDITGENE ITGB8 Knockout in HeLa is highly informative — αvβ8 is a major mechanism of latent TGF-β activation in vivo, particularly in dendritic cells, regulatory T cells, and brain pericytes. Rescue with wild-type or RGD-binding-deficient ITGB8 is the standard specificity control. The knockout is a critical specificity tool for anti-αvβ8 antibodies (e.g., 37E1, PF-06940434, BG00011/STX-100 related) in clinical development for cancer immunotherapy — αvβ8 inhibition releases tumor-immunosuppressive TGF-β from latent stores and enhances anti-PD-1 responses.

Yes. ITGB8 rescue experiments require attention to αv heterodimer formation: • Construct design: use a codon-modified ITGB8 sequence with a small intracellular C-terminal tag (FLAG, HA). ITGB8 has extracellular β-I domain (RGD binding), single transmembrane span, and short cytoplasmic tail — preserve all elements. • Surface localization validation: confirm plasma membrane αvβ8 heterodimer formation by cell surface staining before functional assays. • RGD-binding-deficient rescue: β-I domain MIDAS site mutations abolish RGD binding and serve as the standard specificity control. • ITGAV partnership: ITGB8 requires ITGAV for surface expression — rescue interpretation considers αv levels. • Functional readout: rescue should restore αvβ8-dependent latent TGF-β activation measured by SMAD2/3 phosphorylation. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying HPS1's role as a BLOC-3 complex subunit or modeling Hermansky-Pudlak syndrome type 1 with its characteristic pulmonary fibrosis. The Knockout line is the standard tool for asking whether HPS1 is required for these processes — HPS1 partners with HPS4 to form the BLOC-3 (biogenesis of lysosome-related organelles complex 3), a GEF for Rab32/Rab38 that controls the formation and maturation of lysosome-related organelles (LROs) including melanosomes, platelet dense granules, and lung lamellar bodies. Overexpression is useful for studying HPS1 in heterologous expression contexts. For pulmonary disease research, the EDITGENE HPS1 Knockout in A-549 is highly relevant — A-549 is an alveolar type II cell-like cancer line, and HPS1 mutations cause Hermansky-Pudlak syndrome type 1 with characteristic pulmonary fibrosis (HPS-related interstitial pneumonia, HPSIP) due to defective alveolar type II cell lamellar body biogenesis and surfactant secretion. Rescue with wild-type or HPS4-binding-deficient HPS1 enables structure-function studies. The knockout is valuable for studying HPS pulmonary fibrosis mechanisms and emerging HPS1-related therapeutic approaches.

Yes. HPS1 rescue experiments require attention to BLOC-3 complex assembly: • Construct design: use a codon-modified HPS1 sequence with a small C-terminal tag (FLAG, HA). HPS1 has N-terminal HPS4-interaction region and C-terminal Rab32/Rab38 GEF region — preserve all elements. • HPS4-binding-deficient rescue: HPS4-interaction surface mutations disrupt BLOC-3 complex formation. • HPS mutation rescue: patient-derived HPS1 mutations (e.g., founder Puerto Rican 16-bp duplication) enable disease genotype-function studies. • Functional readout: rescue should restore lysosome-related organelle biogenesis (in melanocyte/platelet contexts) and surfactant lamellar body formation in alveolar contexts. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying IL1RL1 (ST2)'s role as the IL-33 receptor or modeling its functions in Th2 immunity and asthma. The Knockout line is the standard tool for asking whether ST2 is required for IL-33 signaling — IL1RL1 partners with IL1RAP to form the IL-33 receptor complex; upon IL-33 binding, the complex assembles and activates MyD88-IRAK-NF-κB signaling, driving Th2 cytokine production and ILC2 activation. Overexpression is useful for studying ST2 in heterologous expression contexts. Important consideration: IL1RL1 is principally expressed in mast cells, Th2 cells, ILC2s, basophils, and eosinophils — HCT 116 is not the canonical physiological context, but HCT 116 has been characterized for IL-33-ST2 signaling in colorectal cancer biology. The EDITGENE IL1RL1 Knockout in HCT 116 enables study of IL-33-ST2 signaling in colorectal cancer context. Rescue with wild-type or IL1RAP-binding-deficient ST2 is the standard specificity control. The knockout is a critical specificity tool for tezepelumab (anti-TSLP, indirect effect on ST2 pathway, FDA-approved for severe asthma) and astegolimab/itepekimab/etokimab (anti-ST2/IL-33 antibodies in clinical development for asthma and atopic dermatitis).

Yes. ST2 rescue experiments require attention to receptor architecture and isoforms: • Construct design: use a codon-modified IL1RL1 sequence with a small intracellular C-terminal tag (FLAG, HA). IL1RL1 has long (ST2L, full-length membrane-bound) and short (sST2, soluble) isoforms with different functions — choose the isoform appropriate to the experimental question. • Surface localization validation: confirm plasma membrane localization for ST2L isoform; confirm secretion for sST2. • IL1RAP-binding-deficient rescue: extracellular domain mutations disrupt IL1RAP co-receptor partnership. • Functional readout: rescue should restore IL-33-induced phospho-IκBα and Th2 cytokine target gene expression (for ST2L) or IL-33 sequestration (for sST2). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying Il4i1 (interleukin-4-induced 1, IL4-induced gene 1)'s role as a secreted L-amino acid oxidase or its emerging functions in tumor immunosuppression. The Knockout line is the standard tool for asking whether Il4i1 is required for these processes — Il4i1 is a secreted enzyme that oxidatively deaminates L-amino acids (particularly phenylalanine, tryptophan, and tyrosine), generating H₂O₂, ammonia, and α-keto acids. Tryptophan-derived indole-3-pyruvate from Il4i1 activates the aryl hydrocarbon receptor (AhR), driving immunosuppression. Overexpression is useful for studying Il4i1 in heterologous expression contexts. For tumor immunology research, the EDITGENE Il4i1 Knockout in MC-38 is highly relevant — MC-38 is a murine colon adenocarcinoma cell line widely used for syngeneic tumor immunology research in C57BL/6 mice, and Il4i1 has emerged as a major immunosuppressive tumor-intrinsic factor through AhR activation. Rescue with wild-type or catalytically-dead Il4i1 is the standard specificity control. The knockout is valuable for studying tumor immune evasion mechanisms, AhR-mediated immunosuppression, and emerging Il4i1-targeted immuno-oncology drug development — Il4i1 has been compared to IDO1 as a tryptophan-metabolism-based immunosuppression axis.

Yes. Il4i1 rescue experiments are well-established for tumor immunology research: • Construct design: use a codon-modified Il4i1 sequence with a small C-terminal tag (FLAG, HA). Il4i1 has N-terminal signal peptide (secreted enzyme), FAD-binding domain, and substrate-binding pocket — preserve all elements. • Catalytically-dead rescue: FAD-binding residue mutations abolish L-amino acid oxidase activity and serve as the standard specificity control. • Secreted enzyme considerations: Il4i1 is secreted — rescue interpretation considers conditioned media transfer or co-culture studies. • In vivo syngeneic rescue: MC-38 cells with Il4i1 rescue can be implanted in C57BL/6 mice for tumor growth and immune profiling studies. • Functional readout: rescue should restore cellular indole-3-pyruvate generation and AhR pathway activation in TME-relevant contexts. MC-38-specific considerations: • MC-38 is a chemically induced murine colon adenocarcinoma cell line (C57BL/6 origin) — widely used for syngeneic tumor immunology research given its immunogenicity in immunocompetent C57BL/6 hosts. • Lentiviral transduction is supported with moderate efficiency; characterize basal MHC class I expression and immune marker profile before phenotypic studies. • MC-38 is responsive to immune checkpoint inhibitors, making it relevant for studying tumor-intrinsic immune evasion mechanisms.

The choice depends on whether you are studying IL4I1 (interleukin 4-induced 1, IL4-induced gene 1)'s role as a secreted L-amino acid oxidase or its functions in human myeloid cell biology and tumor immunosuppression. The Knockout line is the standard tool for asking whether IL4I1 is required for these processes — IL4I1 is a secreted enzyme that oxidatively deaminates L-amino acids (particularly phenylalanine, tryptophan, and tyrosine), generating H₂O₂, ammonia, and α-keto acids; tryptophan-derived indole-3-pyruvate from IL4I1 activates the aryl hydrocarbon receptor (AhR), driving immunosuppression. Overexpression is useful for studying IL4I1 in heterologous expression contexts. For human tumor immunology research, the EDITGENE IL4I1 Knockout in THP-1 is highly relevant — THP-1 is a human acute monocytic leukemia cell line providing a myeloid context for IL4I1 study, where IL4I1 has emerged as a major tumor-associated immunosuppressive factor in tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells. This product complements the parallel Il4i1 Knockout in MC-38 (mouse colon cancer, also available) for cross-species tumor immunology studies. Rescue with wild-type or catalytically-dead IL4I1 enables structure-function studies. The knockout is valuable for studying IL4I1-targeted immuno-oncology drug development — IL4I1 has been compared to IDO1 as a tryptophan-metabolism-based immunosuppression axis.

Yes. IL4I1 rescue experiments are well-established for tumor immunology research: • Construct design: use a codon-modified IL4I1 sequence with a small C-terminal tag (FLAG, HA). IL4I1 has N-terminal signal peptide (secreted enzyme), FAD-binding domain, and substrate-binding pocket — preserve all elements. • Catalytically-dead rescue: FAD-binding residue mutations abolish L-amino acid oxidase activity and serve as the standard specificity control. • Secreted enzyme considerations: IL4I1 is secreted — rescue interpretation considers conditioned media transfer or co-culture studies. • Functional readout: rescue should restore cellular indole-3-pyruvate generation and AhR pathway activation. THP-1-specific considerations: • THP-1 is a human acute monocytic leukemia cell line widely used as a monocyte/macrophage model — PMA differentiation generates adherent macrophage-like cells. • Lentiviral transduction efficiency is moderate; suspension and adherent (post-PMA) phenotypes should be characterized separately. • THP-1 retains key monocyte/macrophage markers and TLR responses, making it relevant for myeloid-context Il4i1 studies.